<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490814</url>
  </required_header>
  <id_info>
    <org_study_id>FI-123</org_study_id>
    <nct_id>NCT01490814</nct_id>
  </id_info>
  <brief_title>FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation</brief_title>
  <official_title>A Controlled, Prospective, Non-Inferiority, Parallel-Group, Randomised, Interventional, Open, Blinded Outcome Assessment (PROBE-Design), Multi-centre Trial, Comparing Efficacy and Safety of Isolation of the PVs With a Cryoballoon Catheter vs a Radiofrequency Ablation With a ThermoCool Catheter in Patients With PAF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic International Trading Sarl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic International Trading Sarl</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon
      catheter versus a radiofrequency ablation with a ThermoCool catheter in patients with
      paroxysmal atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this randomized clinical trial is to compare the efficacy and safety of
      isolating the PVs with either the cryoballoon or a RF ablation technique with a ThermoCool
      catheter, a system which can be regarded as standard for ablation. In total 762 patients with
      paroxysmal atrial fibrillation has been randomized for either radiofrequency (RF) or
      cryoballoon. With both techniques, PV isolation will be performed. Primary end point of the
      trial is the time to first recurrence of atrial arrhythmias or prescription of
      anti-arrhythmic drugs after a blanking period of three months. Treatment success will be
      evaluated by using weekly electrocardiography (ECG) monitoring (transtelephonic
      transmission/Tele-ECG) and using Holter electrocardiograms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first documented recurrence of atrial arrhythmias (a blanking period of three months will be maintained after the initial procedure).</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to the first occurrence of each of the components of the primary outcome</measure>
    <time_frame>18 months</time_frame>
    <description>The secondary outcome parameters are defined as all-cause death; Arrhythmia-related death; total procedural duration; total time of fluoroscopy; time to the first occurrence of each of the components of the primary outcome; time to recurrent atrial fibrillation (AF); time to first cardiovascular hospitalization; number of cardiovascular hospitalizations (over-night stays); quality of life changes at 12 months compared to baseline; time to first symptomatic AF recurrence;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">769</enrollment>
  <condition>Symptomatic Paroxysmal Atrial Fibrillation (PAF)</condition>
  <arm_group>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrical isolation of the pulmonary veins</intervention_name>
    <description>Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrical isolation of pulmonary veins</intervention_name>
    <description>Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic PAF with at least two episodes and at least one episode documented (30
             seconds episode length, documented by ECG within last 12 months).

          -  Documented treatment failure for effectiveness of at least one anti-arrhythmic
             drug(AAD Type I or III, including β-blocker and AAD intolerance).

          -  ≥ 18 and ≤ 75 years of age.

          -  Patients who are mentally and linguistically able to understand the aim of the trial
             and to show sufficient compliance in following the trial protocol.

          -  Patient is able to verbally acknowledge and understand the associated risks, benefits,
             and treatment alternatives to therapeutic options of this trial: cryoballoon ablation
             system or standard RF ablation technique. The patients, by providing informed consent,
             agree to these risks and benefits as stated in the patient informed consent document.
             All the details have been presented to him and he has signed the informed consent form
             for the trial.

        Exclusion Criteria:

        General exclusion criteria

          -  Any disease that limits life expectancy to less than one year.

          -  Participation in another clinical trial (of a drug, device or biologic), either within
             the past two months or ongoing.

          -  Pregnant women or women of childbearing potential not on adequate birth control: only
             women with a highly effective method of contraception [oral contraception or
             intrauterine device (IUD)] or sterile women can be randomized.

          -  Breastfeeding women.

          -  Substance misuse.

          -  Active systemic infection.

          -  Cryoglobulinaemia.

          -  Previous participation in this clinical trial.

          -  Employment by the sponsor or by the department of any of the investigators.

          -  Close relatives of any of the investigators.

        Exclusion criteria related to a cardiac condition

          -  Patients with prosthetic valves.

          -  Any previous LA ablation or surgery.

          -  Any cardiac surgery or percutaneous coronary intervention (PCI) within three months
             prior to enrollment.

          -  Unstable angina pectoris.

          -  Myocardial infarction within three months prior to enrollment.

          -  Symptomatic carotid stenosis.

          -  Chronic obstructive pulmonary disease with detected pulmonary hypertension.

          -  Any condition contraindicating chronic anticoagulation.

          -  Stroke or transient ischemic attack within six months prior to enrollment.

          -  Any significant congenital heart defect corrected or not (including atrial septal
             defects or PV abnormalities) but not including patent foramen ovale.

          -  New York Heart Association (NYHA) class III or IV congestive heart failure.

          -  EF &lt; 35 % (determined by echocardiography within 60 days of enrollment as documented
             in patient medical history).

          -  Anteroposterior LA diameter &gt; 55 mm (by trans-thoracic echocardiography (TTE or TEE)
             within three months to prior enrollment).

          -  LA thrombus (TEE diagnostic performed on admission).

          -  Intracardiac thrombus.

          -  PV diameter &gt; 26 mm in right sided PVs.

          -  Mitral prosthesis.

          -  Hypertrophic cardiomyopathy (see Appendix IX)

          -  2° (Type II) or 3° atrioventricular block.

          -  Brugada syndrome or long QT syndrome.

          -  Arrhythmogenic right ventricular dysplasia.

          -  Sarcoidosis.

          -  PV stent.

          -  Myxoma.

        Exclusion criteria based on laboratory abnormalities

          -  Thrombocytosis (platelet count &gt; 600,000 / µl), thrombocytopenia (platelet count &lt;
             100,000 / µl).

          -  Any untreated or uncontrolled hyperthyroidism or hypothyroidism.

          -  Severe renal dysfunction (stage V, requiring or almost requiring dialysis, glomerular
             filtration rate (GFR) &lt; 15 ml / min).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Heinz Kuck, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Klinikum St. Georg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Na Homolce Hospital, Cardiology</name>
      <address>
        <city>Prague</city>
        <zip>515030</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Henri Mondor CHU, Service de Cardiologie</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon, Départment de Rythmologie, Hospital Cardiologique Pradel</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Chirurgical Ambroise Paré</name>
      <address>
        <city>Neuilly Sur Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Clinique Pasteur, 45 Avenue de Lombez</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-Zentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Kardiologie II mit interventioneller Elektrophysiologie</name>
      <address>
        <city>Bad Neustadt/Saale</city>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum Bethanien - CCB</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Greifswald Elektrophysiologie</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-Zentrum-Bodensee Konstanz</name>
      <address>
        <city>Konstanz</city>
        <zip>78464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University of Medicine, Kardiovaskuläres Zentrum</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Arrhythmia Research Centre Department of Cardiovascular Medicine Centro Cardiologico Monzino University of Milan</name>
      <address>
        <city>Milan</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken loc. Weezenlanden Diagram Clinical Resarch</name>
      <address>
        <city>Zwolle</city>
        <zip>8011</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic, University of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arrhythmia Unit Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria, Department of Cardiology, Campus Teatinos sn</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universtitario, Cardiology Department Arrhythmia Unit</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel, Elektrophysiologie/ Kardiologie</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/25146732</url>
    <description>Rationale and Design of FIRE AND ICE: A Multicenter Randomized Trial Comparing Efficacy and Safety of Pulmonary Vein Isolation using a Cryoballoon Versus Radiofrequency Ablation with 3D-reconstruction.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/27042964</url>
    <description>Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation.</description>
  </link>
  <link>
    <url>http://www.acc.org/latest-in-cardiology/clinical-trials/2016/04/03/15/28/fire-and-ice</url>
    <description>FIRE AND ICE: LBCT ACC</description>
  </link>
  <reference>
    <citation>Fürnkranz A, Brugada J, Albenque JP, Tondo C, Bestehorn K, Wegscheider K, Ouyang F, Kuck KH. Rationale and Design of FIRE AND ICE: A multicenter randomized trial comparing efficacy and safety of pulmonary vein isolation using a cryoballoon versus radiofrequency ablation with 3D-reconstruction. J Cardiovasc Electrophysiol. 2014 Dec;25(12):1314-20. doi: 10.1111/jce.12529. Epub 2014 Nov 12.</citation>
    <PMID>25146732</PMID>
  </reference>
  <results_reference>
    <citation>Kuck KH, Brugada J, Fürnkranz A, Metzner A, Ouyang F, Chun KR, Elvan A, Arentz T, Bestehorn K, Pocock SJ, Albenque JP, Tondo C; FIRE AND ICE Investigators. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016 Jun 9;374(23):2235-45. doi: 10.1056/NEJMoa1602014. Epub 2016 Apr 4.</citation>
    <PMID>27042964</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>May 9, 2016</last_update_submitted>
  <last_update_submitted_qc>May 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAF</keyword>
  <keyword>two episodes within the last twelve months one episode documented</keyword>
  <keyword>Documented treatment failure of at least one antiarrhythmic</keyword>
  <keyword>drug AAD Type I or III including β-blocker and AAD intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 16, 2017</submitted>
    <returned>March 31, 2017</returned>
    <submitted>March 2, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

